FDA in Transition: Industry Braces for Regulatory Slowdown Summary: Mass layoffs of 3,500 FDA staff and senior leadership under Kennedy’s HHS raises concerns about drug approval delays, increased political influence, and diminished scientific oversight in regulatory decisions. Click to see the full article Merck’s $493M Bet on Oral Peptides Summary: Merck partners with Cyprumed in […]